Stoke Therapeutics (NASDAQ:STOK) PT Raised to $13.00

Stoke Therapeutics (NASDAQ:STOK) had its price target raised by equities research analysts at JPMorgan Chase & Co. from $6.00 to $13.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential downside of 8.26% from the stock’s current price.

Several other brokerages have also recently weighed in on STOK. Needham & Company LLC reissued a “buy” rating and set a $14.00 price objective on shares of Stoke Therapeutics in a research note on Friday, February 16th. Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.63.

Stoke Therapeutics Stock Up 37.7 %

Stoke Therapeutics stock opened at $14.17 on Tuesday. The company’s 50-day moving average price is $5.88 and its 200-day moving average price is $4.95. The company has a market cap of $632.69 million, a PE ratio of -5.98 and a beta of 0.68. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40.

Insiders Place Their Bets

In other news, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the transaction, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $5.74, for a total value of $57,400.00. Following the completion of the sale, the insider now directly owns 16,981 shares of the company’s stock, valued at approximately $97,470.94. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The disclosure for this sale can be found here. Insiders sold a total of 37,615 shares of company stock valued at $212,852 over the last 90 days. Insiders own 12.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in Stoke Therapeutics by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock worth $1,320,000 after purchasing an additional 837 shares during the period. American International Group Inc. raised its holdings in shares of Stoke Therapeutics by 10.9% in the second quarter. American International Group Inc. now owns 10,506 shares of the company’s stock valued at $139,000 after acquiring an additional 1,029 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in Stoke Therapeutics by 46.7% in the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock worth $28,000 after acquiring an additional 1,078 shares during the period. Ensign Peak Advisors Inc bought a new position in Stoke Therapeutics during the 1st quarter worth about $25,000. Finally, Point72 Hong Kong Ltd purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $27,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.